Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3927 Target Snapshot

Replicase polyprotein 1a · SINGLE PROTEIN · Severe acute respiratory syndrome-related coronavirus

Back to Search Search this target Browse approvals Evidence Card
407Compounds
75Assays
4Approved Drugs
366.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Replicase polyprotein 1a shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P0C6U8. Start with COVID-19, then reuse UniProt P0C6U8 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt P0C6U8 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
COVID-19

Replicase polyprotein 1a shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include NIRMATRELVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Replicase polyprotein 1a as ChEMBL target CHEMBL3927, mapped to UniProt P0C6U8. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Replicase polyprotein 1a
SINGLE PROTEIN · Severe acute respiratory syndrome-related coronavirus
As of 2026-09-13
ChEMBL target ID
CHEMBL3927
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0C6U8
Replicase polyprotein 1a
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Replicase polyprotein 1a is the right protein anchor across sources, using UniProt P0C6U8 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameReplicase polyprotein 1a
Target TypeSINGLE PROTEIN
OrganismSevere acute respiratory syndrome-related coronavirus
UniProtP0C6U8
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReplicase polyprotein 1a
UniProt AccessionP0C6U8
Component TypeProtein
Sequence Length4382 aa

Replicase polyprotein 1a

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Replicase polyprotein 1a, mapped to UniProt P0C6U8. Sequence length is 4382 aa.

Mapped IDP0C6U8
Review nameReplicase polyprotein 1a
OrganismSevere acute respiratory syndrome-related coronavirus
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Replicase polyprotein 1a shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Late clinical Phase III
influenza
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Late clinical Phase III
pneumonia
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Late clinical Phase III
severe acute respiratory syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Clinical signal Phase II
long COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Clinical signal Phase I
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugNIRMATRELVIR
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries late clinical support. Linked drugs include NIRMATRELVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase III
1
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50261.0
KI92.0
EC5010.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2435614 8.2 Ki 6.3 Preclinical
CHEMBL497141 8.12 Ki 7.5 Preclinical
CHEMBL5565685 7.85 IC50 14.0 Preclinical
CHEMBL5195325 7.82 IC50 15.2 Preclinical
CHEMBL2435614 7.8 Kd 16.0 Preclinical
CHEMBL4802135 7.7 IC50 20.0 Approved
CHEMBL2435605 7.66 Ki 22.0 Preclinical
CHEMBL2435617 7.58 Ki 26.0 Preclinical
CHEMBL2435612 7.55 Ki 28.0 Preclinical
CHEMBL5570210 7.52 IC50 30.0 Preclinical
Distribution

pChEMBL Value Distribution

56
5.0
35
5.5
33
6.0
12
6.5
21
7.0
9
7.5
2
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

NIRMATRELVIR
CHEMBL4802135
Approved 2023
Properties Compare Identifier
Assay Landscape

Assay Landscape

75
Total Assays
237
Tested Compounds
2
Assay Types
Binding — 74 assays, 237 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 49 148 5.5
single protein format 25 89 5.2
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine